You are not currently logged in.
Access JSTOR through your library or other institution:
Live Subgroup B Respiratory Syncytial Virus Vaccines That Are Attenuated, Genetically Stable, and Immunogenic in Rodents and Nonhuman Primates
James E. Crowe Jr., Phuong T. Bui, Cai-Yen Firestone, Mark Connors, William R. Elkins, Robert M. Chanock and Brian R. Murphy
The Journal of Infectious Diseases
Vol. 173, No. 4 (Apr., 1996), pp. 829-839
Published by: Oxford University Press
Stable URL: http://www.jstor.org/stable/30132585
Page Count: 11
Preview not available
Optimal immunization of neonates against disease caused by respiratory syncytial virus (RSV) probably will require multiple doses of a vaccine containing viruses of both subgroups A and B. Live subgroup B RSV mutants were generated containing multiple attenuating mutations, ts (temperature-sensitive) and non-ts (host range), that were introduced by prolonged passage in cell culture or by chemical mutagenesis. The cold-passaged (cp)-52 mutant was restricted in replication compared to wild type virus in rodents and nonhuman primates. In addition, the attenuation phenotype of cp-52 was stable after prolonged replication in immunosuppressed rodents. One or two ts mutations were then introduced into the cp-52 mutant to generate additional candidate vaccine strains that were more attenuated in vivo than the cp-52 parental virus. Tests in humans are being done to determine if one or more of the RSV B-l mutants exhibit a satisfactory balance between attenuation and immunogenicity.
The Journal of Infectious Diseases © 1996 Oxford University Press